- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02958813
An Integrated HIV Prevention Model for African American Mothers and Daughters (IMARA)
This study has three specific aims:
To conduct a 2-arm randomized controlled trial comparing IMARA to a family-based health program (FUELTM). The investigators will:
a. Randomly assign 300 14-18 year-old AA or black girls and their primary female caregivers to IMARA (N=150) or FUELTM (N=150). Women and girls will be recruited four ways: 1) from mental health clinics using clinic liaisons, 2) flyers will be posted in clinic recruitment sites and other agencies instructing interested families to call our recruiter, 3) IMARA participants will hand flyers to interested women and girls they know, and 4) COIP field station staff will pass out flyers and recruit interested women and girls at the field stations and in the community. Investigators will examine the effects of IMARA on women and girls' sexual behavior at 6- and 12-months.
To evaluate the impact of IMARA on theoretical mediators posited by the Theory of Gender and Power and the Social-Personal framework associated with AA women and girls' risky sex. Investigators will:
- Assess changes in women and girls' Individual Attributes (HIV/AIDS knowledge, attitudes, and beliefs, mental health/emotion regulation, ethnic identity); Peer and Partner Processes (partner characteristics, relationship power dynamics, peer influences, partner communication); and Family Context (mother-daughter relationship and communication, parental monitoring) at baseline and follow-ups.
- Evaluate mediation and moderation of theoretical mechanisms on women and girls' sexual behavior.
To assess the impact of IMARA compared to FUELTM on sexually transmitted infections (STIs). Investigators will:
- Test women and girls' urine for three common STIs at baseline and 12-month follow up.
- Explore linkages between biological outcomes and targeted mediators and moderators of change.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Disproportionate rates of mental illness and HIV/STIs among African Americans (AA) reflect significant health disparities. AAs account for more HIV/AIDS cases, people living with HIV/AIDS, and HIV-related deaths than any other racial group in the US. In 2004, HIV was the 3rd leading cause of death among Black women, and in 2006, AA women accounted for 66% of new AIDS cases among women. AA youth ages 13 - 19 comprise approximately 16% of US teens but 69% of new AIDS cases. Most infections among AA women and girls occur through sexual activity, and AA girls report more risky sex, less condom use, and lower perceived HIV risk than AA boys. Racial disparities also exist for AAs in rates of gonorrhea, chlamydia, and syphilis. Among 15 - 19 year old AA girls, gonorrhea rates are higher than any other race/age/gender group, and almost half of AA women have an STI. Important linkages exist between HIV/STIs and mental health; Mental illness is linked to HIV through greater risk taking, poor health promotion, and reduced effects of behavioral interventions for teens and adults.
HIV-risk factors extend beyond individual women or girls, yet few family-based, gender-specific, Afrocentric programs simultaneously address AA women, AA girls, mental health, and the mother-daughter dyad, thereby missing a critical opportunity to address HIV in a broader social context. Interventions that are sensitive to gender and culture focus on women (SISTA) or girls (SiHLE) and lack a mental health and family component. Family-based HIV prevention programs rarely address gender and culture or the adult family member's HIV risks (Project STYLE). Simultaneously targeting multiple levels in an integrated program -- the mother-daughter dyad, women, and girls -- capitalizes on the reciprocal impact of mothers and daughters, and facilitates mutual reinforcement of prevention attitudes and behavior, thereby reducing intervention decay and sustaining positive outcomes over time.
IMARA (Informed, Motivated, Aware, and Responsible about AIDS) blends gender and ethnic components of SISTA and SiHLE (gender roles, ethnic pride, relationship power) with family and mental health components from Project STYLE (affect management, parental monitoring, adolescent development, parent-child communication) to create a culturally relevant, multi-level, integrated, family-based, HIV and mental health prevention program that simultaneously targets AA women and their daughters. Based on the Theory of Gender and Power, the Social-Personal model of HIV-risk, and findings from the investigator's research, IMARA emphasizes the interplay of family, peer, partner, and individual mechanisms as mediators of sexual risk taking for women and girls. Pilot testing (N=22 dyads) revealed strong feasibility, acceptability, and tolerability: >95% consent/assent rates, 96% retention at 2-month follow-up, and very positive feedback. Promising outcome data for mothers and daughters in targeted mediators (e.g., positive attitudes about HIV/AIDS, greater intentions to use condoms, increased parental monitoring, more open mother-daughter communication, more relationship power) and sexual risk outcomes (e.g., increased condom use, fewer partners) justify a randomized controlled trial.
This study has three specific aims:
To conduct a 2-arm randomized controlled trial comparing IMARA to a family-based health program (FUELTM). Investigators will:
a. Randomly assign 300 14-18 year-old AA or black girls and their primary female caregivers to IMARA (N=150) or FUELTM (N=150). Women and girls will be recruited four ways: 1) from mental health clinics using clinic liaisons, 2) flyers will be posted in clinic recruitment sites and other agencies instructing interested families to call the study recruiter, 3) IMARA participants will hand flyers to interested women and girls they know, and 4) COIP field station staff will pass out flyers and recruit interested women and girls at the field stations and in the community. Investigators will examine the effects of IMARA on women and girls' sexual behavior at 6- and 12-months.
To evaluate the impact of IMARA on theoretical mediators posited by the Theory of Gender and Power and the Social-Personal framework associated with AA women and girls' risky sex. Investigators will:
- Assess changes in women and girls' Individual Attributes (HIV/AIDS knowledge, attitudes, and beliefs, mental health/emotion regulation, ethnic identity); Peer and Partner Processes (partner characteristics, relationship power dynamics, peer influences, partner communication); and Family Context (mother-daughter relationship and communication, parental monitoring) at baseline and follow-ups.
- Evaluate mediation and moderation of theoretical mechanisms on women and girls' sexual behavior.
To assess the impact of IMARA compared to FUELTM on sexually transmitted infections (STIs). Investigators will:
- Test women and girls' urine for three common STIs at baseline and 12-month follow up.
- Explore linkages between biological outcomes and targeted mediators and moderators of change.
Hypotheses
IMARA participants will report less risky sex (fewer partners, more consistent condom use, and later sexual debut among non-sexually active girls) at 6- and 12-months and have fewer incident STI infections at 12-months; and (b) IMARA participants will report positive changes in theoretical mediators: individual attributes (more positive condom attitudes, self-efficacy, ethnic pride), peer/partner influences (more relationship power, partner communication, and awareness of partner influences on sexual decision making), mental health (improved emotion regulation and understanding of the links between mental illness and risky sex), mother-daughter communication (more open and comfortable), and mother-daughter relationships (more parental monitoring and warmth, less parental permissiveness).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adolescent girls between 14-18 years of age, African American or Black.
- Women who are primary female caregivers and self-identify as African American or Black, and are over the age of 18.
- Women and daughters must agree to participate as a dyad.
Exclusion Criteria:
- If either participant is unable to understand the consent/assent process, do not speak English, are actively psychotic or severely mentally ill, or girls do not live with participating female caregiver.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMARA
IMARA blends three programs with the most relevance for AA women (SISTA) and girls (SiHLE) and families in psychiatric care (Project STYLE).
Separate mother and daughter groups cover parallel content and run simultaneously, and joint activities enhance mothers' credibility as a resource for HIV/STI prevention, practice new communication skills, negotiate conflict, and strengthen the mother-daughter relationship.
Activities reinforce the reciprocal impact of mothers and daughters, and enhance safe sex knowledge, attitudes, and skills.
Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
|
Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride.
IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation.
Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program.
At the end of day 1, mothers and daughters receive homework for the week.
Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
|
Placebo Comparator: FUEL
FUEL Health Promotion Control combines two programs, FUEL and Project Balance Health Promotion.
FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior.
FUEL™ does not explicitly address HIV/STI prevention.
Investigators will present information from Balance's session about HIV/AIDS, condoms, and other STIs.
Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
|
FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA.
FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior.
Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Risky Sexual Behavior
Time Frame: From Baseline to 6 month followup
|
The AIDS-Risk Behavior Assessment (ARBA) is a computer-assisted interview of sexual behavior and drug use.
The ARBA was derived from five established measures used in large-scale studies to examine HIV/AIDS-risk in youth and adults.
The ARBA assesses substance use, sexual behavior, and needle use.
Investigators will assess mothers and daughters' condom use, sex with high-risk partners, sex while using drugs/alcohol, number of partners, sexual debut -- and relative frequency and count-based indicators.
|
From Baseline to 6 month followup
|
Change in Incident STI infection
Time Frame: From Baseline to 12 month followup
|
Investigators will measure women's and girls' STIs using biological endpoints (yes/no) to evaluate intervention effects.
Investigators will screen urine for three sexually transmitted pathogens at baseline and 12- month follow up; N. gonorrhoeae, C. trachomatis, and T.vaginalis.
Investigators will use nucleic acid amplification technologies (NAAT) for STI testing.
|
From Baseline to 12 month followup
|
Change in Risky Sexual Behavior
Time Frame: From Baseline to 12 month followup
|
The AIDS-Risk Behavior Assessment (ARBA) is a computer-assisted interview of sexual behavior and drug use.
The ARBA was derived from five established measures used in large-scale studies to examine HIV/AIDS-risk in youth and adults.
The ARBA assesses substance use, sexual behavior, and needle use.
Investigators will assess mothers and daughters' condom use, sex with high-risk partners, sex while using drugs/alcohol, number of partners, sexual debut -- and relative frequency and count-based indicators.
|
From Baseline to 12 month followup
|
Change in Peer and Partner Processes
Time Frame: From Baseline to 6 month followup
|
Investigators will measure changes in women and girls' Peer and Partner Processes such as partner characteristics, relationship power dynamics, peer influences, and partner communication.
|
From Baseline to 6 month followup
|
Change in Peer and Partner Processes
Time Frame: From Baseline to 12 month followup
|
Investigators will measure changes in women and girls' Peer and Partner Processes such as partner characteristics, relationship power dynamics, peer influences, and partner communication.
|
From Baseline to 12 month followup
|
Change in Individual Attributes
Time Frame: From Baseline to 6 month followup
|
Investigators will measure changes in women and girls' Individual Attributes such as HIV/AIDS knowledge, attitudes, and beliefs, mental health/emotion regulation, and ethnic identity.
|
From Baseline to 6 month followup
|
Change in Individual Attributes
Time Frame: From Baseline to 12 month followup
|
Investigators will measure changes in women and girls' Individual Attributes such as HIV/AIDS knowledge, attitudes, and beliefs, mental health/emotion regulation, and ethnic identity.
|
From Baseline to 12 month followup
|
Change in Family Context
Time Frame: From Baseline to 6 month followup
|
Investigators will measure changes in women and girls' Individual Attributes such as Family Context (mother-daughter relationship and communication, and parental monitoring)
|
From Baseline to 6 month followup
|
Change in Family Context
Time Frame: From Baseline to 12 month followup
|
Investigators will measure changes in women and girls' Individual Attributes such as Family Context (mother-daughter relationship and communication, and parental monitoring)
|
From Baseline to 12 month followup
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2011-01627
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Prevention
-
Prof Mags BeksinskaCompletedHIV Prevention | Pregnancy PreventionSouth Africa
-
Yale UniversityCompletedHIV Prevention | STI PreventionUnited States
-
Centers for Disease Control and PreventionUniversity of Minnesota; The Fenway Institute; AIDS Action Committee of Massachusetts and other collaboratorsCompletedHIV Prevention | STD PreventionUnited States
-
International Partnership for Microbicides, Inc.CompletedHIV PreventionSouth Africa, Uganda
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompleted
-
Fenway Community HealthCompleted
-
University of California, Los AngelesUniversity of California, San Diego; California HIV/AIDS Research Program; Los... and other collaboratorsCompletedHIV PreventionUnited States
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHIV PreventionUganda, South Africa, Zimbabwe
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompleted
-
Orion Biotechnology Polska Sp. z o.o.Scope International AGCompleted
Clinical Trials on IMARA
-
Emory UniversityCenters for Disease Control and PreventionCompletedHIV InfectionsUnited States
-
University of Illinois at ChicagoUniversity of MichiganNot yet recruitingHIV Infections | Sexual Behavior | Sexually Transmitted Infections (Not HIV or Hepatitis)United States
-
University of Illinois at ChicagoEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingA Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women (IMARA-SA)HIV Infections | Sexually Transmitted InfectionsSouth Africa
-
University of Illinois at ChicagoEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHiv | Sexually Transmitted InfectionSouth Africa